Targeting specific immune cells to improve treatment for advanced prostate cancer
Therapeutic targeting of CD206+ TAMs to enhance adaptive and innate anti-tumor immune responses in metastatic castration-resistant prostate cancer
This study is looking at a new treatment for men with advanced prostate cancer that aims to boost the body's immune response by targeting certain cells that make it harder for the immune system to fight the cancer, and it may involve patients trying out this promising new therapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10880701 on NIH RePORTER |
What this research studies
This research focuses on metastatic castration-resistant prostate cancer (mCRPC), which is characterized by immune suppressive tumor-associated macrophages (TAMs) that hinder effective immune responses. The study aims to enhance anti-tumor immune responses by targeting CD206, a receptor on these TAMs, using a novel therapeutic agent called RP-182. By reprogramming these immune cells, the research seeks to improve the effectiveness of existing cancer therapies and potentially restore the body's ability to fight the cancer. Patients may be involved in clinical trials that assess the safety and efficacy of this new approach.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with metastatic castration-resistant prostate cancer who have not responded adequately to current therapies.
Not a fit: Patients with early-stage prostate cancer or those whose cancer has not metastasized may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with advanced prostate cancer, enhancing their immune response against tumors.
How similar studies have performed: Previous research has shown promise in targeting immune cells to enhance cancer treatment, suggesting that this approach could be effective.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Zarif, Jelani Chinelo — Johns Hopkins University
- Study coordinator: Zarif, Jelani Chinelo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.